E-selectin Inhibitor Plaque Stabilization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective solutions to inhibit the inflammatory cascade and immune cell proliferation/activation responses contributing to atherosclerotic injury, which are key factors in cardiovascular diseases such as myocardial infarction and atherosclerosis.
Innovation Solution
Administration of an effective amount of an E-selectin inhibitor to subjects in need, which reduces the recruitment and infiltration of inflammatory myeloid cells to atherosclerotic plaques, thereby stabilizing plaques and preventing their rupture.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used to treat cardiovascular disease, then general cardiovascular support is provided, but they fail to effectively inhibit the inflammatory cascade and immune cell proliferation contributing to atherosclerotic injury
Solution Approach 1:
The patent segments the broad cardiovascular disease treatment into a specific pathway targeting the inflammatory cascade. By focusing on E-selectin inhibition, the therapy isolates and addresses the specific mechanism of leukocyte recruitment and plaque inflammation, rather than treating cardiovascular disease generally. This segmentation allows for targeted intervention in the inflammatory pathway while maintaining overall cardiovascular health.
Solution Approach 2:
The patent changes the therapeutic parameter from general cardiovascular support to specific inhibition of E-selectin-mediated adhesion. By altering the mechanism of action to target selectin pathways, the therapy achieves enhanced effectiveness in preventing atherosclerotic progression through reduced inflammatory cell infiltration and plaque stabilization.
2Stability of the object's composition
If E-selectin inhibitors are administered to reduce inflammatory cell recruitment, then plaque stability is improved, but the complexity of the treatment regimen increases
Solution Approach 1:
The patent uses E-selectin inhibitors as intermediary agents that block the interaction between endothelial cells and circulating leukocytes. By introducing this intermediary substance that specifically binds to E-selectin, the treatment simplifies the complex inflammatory process into a single targetable interaction, making the overall treatment approach more manageable despite the biological complexity of atherosclerosis.
Data Source
AI summary
New methods for treating and/or preventing cardiovascular disease including, for example, myocardial infarction and atherosclerosis, by the use of at least one E-selectin inhibitor and compositions comprising the same are disclosed.